Dire score 2025

Show details

4.2 out of 5

38 votes

The document outlines the DIRE Score system for assessing patient suitability for chronic opioid analgesia. It provides a scoring framework based on four factors: Diagnosis, Intractability, Risk, and Efficacy, with each factor rated from 1 to 3. The total score determines whether a patient is a suitable candidate for long-term opioid treatment, with scores of 7-13 indicating unsuitability and scores of 14-21 suggesting potential suitability.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

How to edit Dire score online

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

With DocHub, making adjustments to your documentation takes only some simple clicks. Make these fast steps to edit the PDF Dire score online free of charge:

Register and log in to your account. Log in to the editor using your credentials or click on Create free account to test the tool’s functionality.
Add the Dire score for editing. Click on the New Document option above, then drag and drop the file to the upload area, import it from the cloud, or via a link.
Alter your file. Make any adjustments needed: insert text and images to your Dire score, underline details that matter, remove parts of content and substitute them with new ones, and insert symbols, checkmarks, and areas for filling out.
Finish redacting the template. Save the modified document on your device, export it to the cloud, print it right from the editor, or share it with all the people involved.

Our editor is very easy to use and effective. Try it out now!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

What is the drug risk score?

The Milliman Rx Risk Score is a proprietary scoring algorithm that uses prescription drug history to predict the mortality risk of individuals relative to other individuals of the same age and gender.

What are the 4 Ps of pain management?

When a pain becomes chronic, there are other associated changes in the brain that can contribute to a disability, anxiety, depression, lack of sleep, or poor quality of life. The most effective pain management treatment uses a combination of the 4Ps: prevention, psychological, physical, and pharmaceutical.

What is the dire assessment?

Assesses the risk of opioid abuse and suitability of candidates for long-term opioid therapy in primary care.

What are the 4 classes of opioid receptors?

Opioid receptors are classified as (mu, MOP), (delta, DOP) and (kappa, KOP); these are naloxone-sensitive and possess endogenous peptide ligands. The fourth opioid receptor is that for nociceptin/orphanin FQ (N/OFQ) or NOP and is naloxone-insensitive.

What are the 5 As of opioid prescribing?

Regular assessment with the 5 As (i.e., analgesia, activity, adverse effects, aberrant behaviors, and affect) Periodically review pain diagnosis and comorbid conditions, including substance use disorders.

What are the 4 As of opioid prescribing?

Like other treatments, opioid therapy should be continued only so long as it is effective. Many clinicians have found it useful to monitor and document opioid response using the 4As of Passik and colleagues (2004): analgesia, activities of daily living, adverse events, and ADRBs.

What is the dire score?

The DIRE Score is a clinician rating designed for the primary care physician. It is used to predict efficacy of analgesia and patient compliance with long-term opioid analgesic treatment.

What are the new guidelines for opioid prescribing?

The 2022 guideline further suggests that clinicians evaluate benefits and risks with patients within 1-4 weeks of starting opioid therapy for subacute or chronic pain or of dosage escalation. This recommendation is particularly relevant to the chronic management of patients who begin opioids for hidradenitis

Dire score 2025

Here's how it works